IVIG in Painful Sensory Neuropathy
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorSorlandet Hospital HF
About this trial
The goal of this clinical trial is to assess effect of Intravenous immunoglobulins (antibodies) as compared to Placebo, on pain intensity in patients from 18-65 years with painful sensory neuropathy without a known cause. Effect of the treatment will be recorded by the patient in a digital diary.
Eligibility criteria
Qualifiers
Idiopathic small fiber neuropathy (all of the following)
Neuropathic pain (length-dependent/non-length dependent/focal) and at least two of the following clinical signs
Hypoesthesia (tactile, pinprick, or thermal)
Allodynia (tactile, dynamic, thermal, pressure)
Disqualifiers
Previous allergic reaction to IVIG or other blood products)
Selective IgA deficiency
Cardiac insufficiency (NYHA III/IV ie marked or severe limitation in activity due to symptoms, even during less-than-ordinary activity)
Cardiac dysrhythmia requiring treatment
Trial design
Treatments tested in this trial
- Intravenous immunoglobulin
- Placebo
Treatment groups
20 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Sorlandet Hospital HF
Lead sponsor
Oslo University Hospital
Collaborator
University Hospital of North Norway
Collaborator
University Hospital of Saint-Etienne
Collaborator
Source ClinicalTrials.gov